Validation of the EasyScreen 3base SARS-CoV-2 Detection Kit RP012 on Saliva Samples

Hear from our Senior Principal Research Scientist, Dr Rohan Baker, in this years’ virtual NRL Workshop on Infectious Diseases. The talk and Q&A discusses the validation of our EasyScreen SARS-CoV-2 Detection Kit on saliva samples, in collaboration with St Vincent’s Health Network Sydney.

Read More

The Burden of Gastrointestinal Parasites and Advances in Ova and Parasite Diagnostic Screening

Webinar 1 thumbnail FINAL

This webinar is the first of a three-part series on Advances in Gastrointestinal Protozoa Testing: Molecular Ova and Parasite Investigations that aims to highlight the prevalence of gastrointestinal (GI) protozoan infection, the significant health and economic burden, and the recent advances in rapid and accurate testing techniques. Traditional screening methods for detecting ova and parasites…

Read More

Molecular O&P – A Streamlined Workflow for Ova and Parasite Testing and Patient Management

Webinar 2 thumbnail FINAL

This webinar is the second of a three-part series on Advances in Gastrointestinal Protozoa Testing. The first webinar gave a broad overview of the key parasites causing gastrointestinal disease, traditional diagnostic methods used to detect ova and protozoa, and the benefits of employing a molecular approach. In this second live webinar, two leading experts in…

Read More

38th NRL Workshop on Infectious Disease Testing – Oct 2022

NRL 2022 Presentation - Australia (Oct 22) - Webinar

Improvement of Syndromic Screening of Respiratory and Enteric Pathogens with Rapid PCR Cycling Genetic Signatures presents optimised cycling times for six key EasyScreenTM respiratory and gastrointestinal detection kits, enabling faster time-to-result to support laboratory workflow and reporting, and improved patient management.

Read More

Genetic Signatures’ CEO, John Melki, talks with Nadine Blayney from AusBiz

ausbiz-john-melki-webinar-thumbnail

Genetic Signatures’ CEO Dr John Melki was recently interviewed by Nadine Blayney from AusBiz about the Company’s unique 3base® technology, its advantages for detecting infectious diseases, the development pipeline, revenue sources, and plans for further investment and expansion in key international markets.

Read More

Biotech Predictions Webinar 2022

Genetic Signatures’ CEO Dr John Melki takes part in the Biotech Predictions webinar, discussing the company’s recent financial summary, our ongoing response to the COVID-19 pandemic, and further global impact with products including gastrointestinal infection and sexual health testing.

Read More